Startup profile · funding coverage
Potential Sciences funding, valuation and investors
Cambridge startup making high-accuracy GPU quantum-chemistry data for molecular AI models.
Verified company research · funding, investors and latest developments
Keep track of Potential Sciences
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Seed financing and compute package
Undisclosed cash; eight figures INCLUDING noncash compute · November 5, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
seed · Cambridge, UK; research in Bristol and Tübingen
Investors in latest funding
Lead: Sovereign AI Fund , Twin Path Ventures
Other: Nauta Capital , Blue Wire Capital , Lightfield Equity , Odyssey , Portfolio Ventures , Rule30
Overview
Founded in Cambridge in 2026 by Hatem Helal, Potential Sciences is developing GPU-native quantum chemistry simulations and atomistic foundation models to support molecule screening and drug discovery. The Sovereign AI Fund and Twin Path Ventures led an announced seed investment joined by Nauta, among others. Investors describe eight figures of capital plus compute, but cash raised, valuation, customers and revenue remain undisclosed.
Why Potential Sciences is interesting
Potential Sciences claims 100x lower cost for gold-standard CCSD(T) computations on GPU; that is a vendor/investor claim, not verified external benchmark. The November 5 financing combines an undisclosed cash investment and compute, so equity proceeds cannot be established.
Product & use cases
Illustrative, not tested customer journey: researchers identify candidate molecules; a GPU-native quantum chemistry solver calculates high-accuracy molecular data; atomistic models learn from the simulations; chemists prioritize synthesis and lab testing. The claimed benefit is less expensive early screening, but no independent benchmark or commercial contract was disclosed.
- Drug lead optimization using simulation-derived data.
- Reaction prediction and covalent drug design research.
- Longer-term molecular models for catalyst and materials science; roadmap, not demonstrated adoption.
Key facts
- Founder Hatem Helal; founded 2026.
- Lead investors Sovereign AI Fund and Twin Path Ventures; Nauta Fund VI's first portfolio investment.
- Cash amount and valuation undisclosed. Eight-figure headline combines capital and compute, not pure equity.
Funding history (newest first)
Seed financing and compute package
2026-11-05 Undisclosed cash; eight figures INCLUDING noncash compute- Sovereign AI Fund (lead)
- Twin Path Ventures (lead)
- Nauta Capital (participant)
- Blue Wire Capital (participant)
- Lightfield Equity (participant)
- Odyssey (participant)
- Portfolio Ventures (participant)
- Rule30 (participant)
Source: Read source · nautacapital.co
Investors in our directory
Funds linked from Potential Sciences's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Nauta's issuer release claims 100x lower CCSD(T) simulation cost than existing implementations; no independent validation, exact workload definition, availability or pricing was disclosed.
Alternatives include conventional high-performance quantum-chemistry pipelines, lower-cost approximate simulation methods, and direct experimental medicinal-chemistry screening. Speed/accuracy trade-offs depend on system and have not been independently benchmarked.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Potential Sciences
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.